Experimental Triple Therapy Improves Survival in Glioblastoma Mouse Model
Jun 4, 2025
Researchers at Brown University are exploring a groundbreaking triple therapy that enhances survival rates in mice with glioblastoma, an aggressive brain cancer. This innovative treatment combines new drugs called imipridones with radiation and chemotherapy, showcasing a promising method to tackle this difficult disease. Glioblastoma's rapid growth often results in poor patient outcomes, making this research crucial. The findings emphasize the potential for more effective therapies against a cancer that currently has limited treatment options.
05:38
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
IRT Triple Therapy Extends Survival
The triple therapy IRT, combining imipridones ONC-201, ONC-206 with radiation and chemotherapy, significantly extends survival in glioblastoma mice.
It slows tumor growth, reduces cancer cell numbers, and makes tumors more sensitive to treatment by lowering MGMT protein levels.
insights INSIGHT
Glioblastoma Aggressiveness Challenges Therapy
Glioblastoma is a highly aggressive brain tumor with poor prognosis, surviving less than 15 months on standard therapies.
Its ability to infiltrate tissue and the blood-brain barrier complicate effective drug delivery.
insights INSIGHT
Imipridones Target Tumor Cells Effectively
ONC 201 and ONC 206 cross the blood-brain barrier and activate cancer cell stress responses leading to cell death.
They disrupt mitochondrial function, increasing tumor sensitivity to radiation and chemotherapy.
Get the Snipd Podcast app to discover more snips from this episode
Researchers at Brown University have developed a combination treatment that significantly increases survival in mice with glioblastoma (GBM), a highly aggressive and treatment-resistant brain cancer. The approach uses a new class of drugs called imipridones along with radiation therapy and standard chemotherapy. This triple therapy, known as IRT, was recently detailed in a study published in Oncotarget.
Understanding Glioblastoma and the Need for Better Therapies
Glioblastoma is the most common and aggressive malignant brain tumor in adults. It grows quickly and is difficult to treat, often leading to poor outcomes. Most patients survive less than 15 months after diagnosis, even when treated with surgery, radiation, and the chemotherapy drug temozolomide (TMZ). This treatment may slow the disease, but it does not typically stop it.
Full blog - https://www.oncotarget.org/2025/06/04/experimental-triple-therapy-improves-survival-in-glioblastoma-mouse-model/
Paper DOI - https://doi.org/10.18632/oncotarget.28707
Correspondence to - Wafik S. El-Deiry - wafik@brown.edu
Video short - https://www.youtube.com/watch?v=Q_mXy8mana0
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, glioblastoma multiforme, IDH, ONC201, ONC206, MGMT, temozolomide, radiotherapy
To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
Oncotarget